All News

How do you plan cash flow with more delays and/or significant reductions looming for Medicare?

Complications after urinary diversion occur often and continue to occur for at least 5 years after surgery.

Although some urologists are intrigued by what the future may hold for immunotherapy, many aren't sure if sipuleucel-T is the treatment that will transform their approach to prostate cancer.

Cigarette smoking is associated with more advanced prostate tumors among men undergoing radical prostatectomy, but there appears to be little difference between smokers and non-smokers when it comes to biochemical recurrence.

The owners of most medical practices feel confident in the service they provide and believe they are both meeting their patients' needs and making a good first impression. But are they? Taking a critical look at the average practice, I'm not so sure.

Urologists share how EMRs, recycling and reducing waste help make their practices reduce their environmental impact.

When an official acting on behalf of a government agency contacts a medical practice, it can be a daunting, even frightening experience-one that requires knowledge of your rights and what you must and should do.

In men with bone metastasis from castration-resistant prostate cancer, a monthly subcutaneous injection with denosumab, 120 mg, is superior to monthly intravenous zoledronic acid (Zometa), 4 mg, for preventing and delaying first on-study and multiple skeletal-related events.

Interim results from a long-term study of active and former chemical industry workers suggest that tumor markers in urine may emerge as a practical and reliable noninvasive diagnostic for bladder cancer.

Datta Wagle, MD, newly appointed 2010-'11 AUA president, discusses current initiatives taking shape at the AUA and the AUA Foundation, as well as his goals and priorities as AUA president.

Irreversible electroporation appears to be a promising nonthermal technique for renal tissue ablation.

During the next few years, insurers will begin demanding evidence that different products and services, such as the robot, truly provide added value in terms of better outcomes and shorter hospital stays.

By this time next year, a new monoclonal antibody positron emission tomography/computed tomography scan may routinely distinguish clear cell renal cell carcinoma from other renal masses before surgery.

Urology Times has appointed J. Brantley Thrasher, MD, to the position of Editorial Consultant, and added Leonard G. Gomella, MD, as a member of its Editorial Council.

The MiniArc Single-Incision Sling System (American Medical Systems, Minnetonka, MN) for female stress urinary incontinence offers efficacy rates of 90.6% for negative cough stress test and 84.5% for the 1-hour pad weight test at 12 months, according to a prospective, multicenter study.

An ultrasensitive PSA test using nanoparticle-based technology may be able to definitively predict whether the cancer is cured long term or if it will recur, new research from Northwestern University?s Feinberg School of Medicine and the University International Institute for Nanotechnology, Chicago shows.

A group of physician-scientists at Memorial Sloan-Kettering Cancer Center has released what it is calling the most comprehensive genomic analysis of prostate cancer to date.

Radical prostatectomy and other surgical patients who participate in longer (15- to 30-minute) informed consent discussions better understand the proposed operation, according to a recent study.

Rep. Tom Rooney (R?FL) has launched a resolution to denote July 17, 2010 as "National Bladder Cancer Awareness Day."

Use of testosterone gel in older men with limited mobility and high rates of chronic illness resulted in higher risk of negative cardiovascular events, according to results of a recent study.

The Centers for Medicare and Medicaid Services has launched a National Coverage Analysis (NCA) of sipuleucel-T (Provenge), a recently approved cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer. The agent is the first in a new therapeutic class known as autologous cellular immunotherapies.

Population screening with the PSA test in men ages 50 to 69 years cut prostate cancer mortality nearly in half during a 14-year follow-up, according to data from a Swedish study published July 1 in the online edition of Lancet Oncology.

FDA has approved cabazitaxel (Jevtana), a chemotherapeutic agent used in combination with prednisone for treatment of advanced, hormone-refractory prostate cancer following docetaxel (Taxotere)-based treatment.

A recent study concludes that statin drugs may lessen the risk for return of prostate cancer in individuals who have undergone radical prostatectomy.

A model predicting the time for stone passage using radiographic parameters was recently validated and now appears to be ready for clinical use.

When I talked to urologists at the recently concluded AUA annual meeting about Richard D. Williams, MD, they all described Dick Williams, the person, first: Unassuming. Dedicated. Soft-spoken. Genuine.

It is, in my opinion, truly amazing how far we have come concerning hypospadias repair.